Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07452094 · ClinicalTrials.gov registry record · Early Phase 1
What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?
A Early Phase 1 study, sponsored by Northern Arizona University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07452094: Clinical Trial Early Phase 1 study, sponsored by Northern Arizona University.
NCT07452094 is a Early Phase 1 study that has not yet begun recruiting, run by Northern Arizona University. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07452094, a Early Phase 1 study, has not yet begun recruiting, sponsored by Northern Arizona University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. These responses must be proportional to the increase in demand and some signal must relay information from the muscle to the brain. Group III/IV afferents do just this. They relay information about the muscle (movement, temperature, acidity, etc.) up to the brain so that appropriate responses are mounted. There is strong evidence in animals that group III/IV afferents play a key role in making breathing easier (decreasing airway resistance) and initiating sweating and blood flow responses. There has been no research on the role of group III/IV afferents on these fundamental exercise responses in humans. The investigators propose to isolate the role of group III/IV afferents on regulate airway resistance, sweating and blood flow responses to exercise in humans.
Primary Outcome
Calculated based of work of breathing and ventilation flow rate
Interventions
- DRUG EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
What is known before NCT07452094 opens enrollment
NCT07452094 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which EXERCISE TRAINING WITH OR WITHOUT MEDICATION is the first listed.
NCT07452094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07452094 about?
NCT07452094 is a clinical study titled "What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?". Exercise places serious demands on the body. These demands are fundamentally caused by increases in oxygen demand and the consequent increase in body temperature. These demands are met by several physiological responses, including increases in heart rate, blood pressure, breathing and blood flow. Th...
What is the current status of trial NCT07452094?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-04-01. Estimated completion is 2027-04-01.
What interventions are being tested in trial NCT07452094?
The interventions under investigation include: EXERCISE TRAINING WITH OR WITHOUT MEDICATION (DRUG).
Who is sponsoring clinical trial NCT07452094?
This trial is sponsored by Northern Arizona University, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07452094's enrollment target sits among peer trials
15 1403rd of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI